ID

25909

Descrizione

A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]; ODM derived from: https://clinicaltrials.gov/show/NCT01022424

collegamento

https://clinicaltrials.gov/show/NCT01022424

Keywords

  1. 26/09/17 26/09/17 -
Caricato su

26 settembre 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0

Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Autosomal Dominant Polycystic Kidney Disease NCT01022424

Eligibility Autosomal Dominant Polycystic Kidney Disease NCT01022424

Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients who completed 3-year repeated administrations and the follow-up observation or those who were withdrawn from the study due to reasons other than occurrence of adverse events (based on the judgment of either the subject or the investigator/subinvestigator) in the preceding study (156-05-002)
Descrizione

Study Subject Participation Status | Protocol Compliance | Patient withdrawn from trial

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2]
C0525058
UMLS CUI [3]
C0422727
patients in whom adverse events occurring in study 156-05-002 were resolved or became stable and do not require further follow-up.
Descrizione

Study Subject Participation Status | Adverse events resolved | Adverse events Stable

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2348568
UMLS CUI [2,1]
C0877248
UMLS CUI [2,2]
C1514893
UMLS CUI [3,1]
C0877248
UMLS CUI [3,2]
C0205360
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
patients with egfr of less than 15 ml/min/1.73 m2
Descrizione

Estimated Glomerular Filtration Rate

Tipo di dati

boolean

Alias
UMLS CUI [1]
C3811844
patients with any of the following complications:
Descrizione

Complications

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0009566
uncontrolled hypertension
Descrizione

Uncontrolled hypertension

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1868885
serious cardiovascular disease (eg. heart failure) or hepatic disease (eg. cirrhosis)
Descrizione

Cardiovascular Diseases Serious | Heart failure | Liver diseases | Liver Cirrhosis

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0007222
UMLS CUI [1,2]
C0205404
UMLS CUI [2]
C0018801
UMLS CUI [3]
C0023895
UMLS CUI [4]
C0023890
patients with any of the following complications or history thereof:
Descrizione

Complications

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0009566
clinically significant drug allergies (anaphylaxis) or hypersensitivity (especially, hypersensitivity to benzazepine derivatives or suspected hypersensitivity
Descrizione

Drug Allergy | Drug related anaphylaxis | Hypersensitivity Benzazepine derivatives | Hypersensitivity Suspected Benzazepine derivatives

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0013182
UMLS CUI [2]
C0850607
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0005034
UMLS CUI [3,3]
C0243072
UMLS CUI [4,1]
C0020517
UMLS CUI [4,2]
C0750491
UMLS CUI [4,3]
C0005034
UMLS CUI [4,4]
C0243072
inability to personally give consent due to a mental illness
Descrizione

Mental disorders Informed Consent Unable

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0004936
UMLS CUI [1,2]
C0021430
UMLS CUI [1,3]
C1299582

Similar models

Eligibility Autosomal Dominant Polycystic Kidney Disease NCT01022424

Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Study Subject Participation Status | Protocol Compliance | Patient withdrawn from trial
Item
patients who completed 3-year repeated administrations and the follow-up observation or those who were withdrawn from the study due to reasons other than occurrence of adverse events (based on the judgment of either the subject or the investigator/subinvestigator) in the preceding study (156-05-002)
boolean
C2348568 (UMLS CUI [1])
C0525058 (UMLS CUI [2])
C0422727 (UMLS CUI [3])
Study Subject Participation Status | Adverse events resolved | Adverse events Stable
Item
patients in whom adverse events occurring in study 156-05-002 were resolved or became stable and do not require further follow-up.
boolean
C2348568 (UMLS CUI [1])
C0877248 (UMLS CUI [2,1])
C1514893 (UMLS CUI [2,2])
C0877248 (UMLS CUI [3,1])
C0205360 (UMLS CUI [3,2])
Item Group
C0680251 (UMLS CUI)
Estimated Glomerular Filtration Rate
Item
patients with egfr of less than 15 ml/min/1.73 m2
boolean
C3811844 (UMLS CUI [1])
Complications
Item
patients with any of the following complications:
boolean
C0009566 (UMLS CUI [1])
Uncontrolled hypertension
Item
uncontrolled hypertension
boolean
C1868885 (UMLS CUI [1])
Cardiovascular Diseases Serious | Heart failure | Liver diseases | Liver Cirrhosis
Item
serious cardiovascular disease (eg. heart failure) or hepatic disease (eg. cirrhosis)
boolean
C0007222 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0018801 (UMLS CUI [2])
C0023895 (UMLS CUI [3])
C0023890 (UMLS CUI [4])
Complications
Item
patients with any of the following complications or history thereof:
boolean
C0009566 (UMLS CUI [1])
Drug Allergy | Drug related anaphylaxis | Hypersensitivity Benzazepine derivatives | Hypersensitivity Suspected Benzazepine derivatives
Item
clinically significant drug allergies (anaphylaxis) or hypersensitivity (especially, hypersensitivity to benzazepine derivatives or suspected hypersensitivity
boolean
C0013182 (UMLS CUI [1])
C0850607 (UMLS CUI [2])
C0020517 (UMLS CUI [3,1])
C0005034 (UMLS CUI [3,2])
C0243072 (UMLS CUI [3,3])
C0020517 (UMLS CUI [4,1])
C0750491 (UMLS CUI [4,2])
C0005034 (UMLS CUI [4,3])
C0243072 (UMLS CUI [4,4])
Mental disorders Informed Consent Unable
Item
inability to personally give consent due to a mental illness
boolean
C0004936 (UMLS CUI [1,1])
C0021430 (UMLS CUI [1,2])
C1299582 (UMLS CUI [1,3])

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial